CompletedPhase 3NCT03374488
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Mark Jones, MDIncyte Corporation
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 84 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (30)
- Ironwood Cancer & Research Centers, Chandler, Arizona, United States
- University of California Irvine Medical Center, Orange, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- UCLA Hematology Oncology Santa Monica, Santa Monica, California, United States
- Smilow Cancer Center at Yale-New Haven, New Haven, Connecticut, United States
- Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States
- University of Chicago, Chicago, Illinois, United States
- Quincy Medical Group, Quincy, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- NYU Clinical Cancer Center, New York, New York, United States
- Oklahoma Cancer Specialists & Research Institute, Tulsa, Oklahoma, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03374488 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- ACTIVE NOT RECRUITINGPHASE1NCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Merck Sharp & Dohme LLC
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
See all trials for Autosomal dominant multiple pterygium syndrome →